A recent Phase 1b clinical study has successfully concluded, testing an innovative immunotherapy for Alzheimer's disease. This trial focused on IBC-Ab002, a humanized anti-PD-L1 monoclonal antibody designed to revitalise systemic immune responses rather than directly targeting amyloid beta plaques, which are traditionally associated with the condition. The results indicate a promising new direction in the treatment of neurodegenerative disorders.
Breakthrough in Alzheimer's Treatment: Targeting Immune System Dysfunction
In a significant development for Alzheimer's research, a Phase 1b clinical trial has confirmed the safety and efficacy of IBC-Ab002, a novel immunotherapy. Conducted across 11 medical centers, including five in the United Kingdom, five in Israel, and one in the Netherlands, the trial involved 40 patients with early-stage Alzheimer's disease. The primary objective was to assess the safety and tolerability of the treatment, which was met successfully across all administered doses. The findings, published in Nature Medicine on August 4, 2026, mark a pivotal moment in the fight against this debilitating disease.
Professor Michal Schwartz, an esteemed researcher from the Weizmann Institute of Science's Brain Sciences Department and a recipient of the Israel Prize in Life Sciences, spearheaded the foundational research behind this immunotherapy. Her pioneering work challenged the long-held belief that the brain was entirely isolated from immune activity, demonstrating instead its critical reliance on the immune system for lifelong functioning, maintenance, and repair. Professor Schwartz's research revealed that age-related immune dysfunction significantly drives brain aging and neurodegenerative disease progression, regardless of the primary cause of such diseases. This insight led to the development of IBC-Ab002, which targets the PD-1/PD-L1 inhibitory immune checkpoint. Unlike conventional treatments that aim to remove amyloid plaques, IBC-Ab002 works by transiently unleashing peripheral immune activity, thereby clearing senescent cells and reducing brain inflammation.
The trial's results showcased several key benefits: IBC-Ab002 was well-tolerated and safe, with no severe adverse reactions or amyloid-related imaging abnormalities. Importantly, biological evaluations showed a reduction in biomarkers associated with active neuronal injury and a reversal of markers linked to synaptic loss. These findings strongly support the innovative paradigm of addressing systemic brain aging by targeting immune exhaustion, offering a fresh perspective on preventing and treating Alzheimer's disease.
The development of IBC-Ab002 was facilitated by ImmunoBrain, a company co-founded by Professor Schwartz to translate her research into practical therapies. The company licensed the technology and intellectual property from Yeda, the Weizmann Institute's tech transfer company. Dr. Tommaso Croese, formerly a PhD student in Schwartz’s lab and now ImmunoBrain's vice president of clinical development, alongside Professor Catherine J. Mummery of University College London’s Dementia Research Centre, led the clinical trial. Collaborators included Dr. Noa Bregman, Dalia Bracha, Dr. Kuti Baruch, Dr. Alexander Kertser, Dr. Sharona Raveh, and Dr. Eliezer Shochat.
Professor Schwartz emphasized that aging is the most significant risk factor for Alzheimer's. Her team's research highlights that the decline in immune system function with age contributes to chronic brain inflammation, a major factor in the progression of Alzheimer's and other neurodegenerative conditions. She believes that restoring the immune system's youthful capacity to protect the brain through biological therapy could halt or even reverse the disease's course, heralding a new era in dementia treatment, especially as global populations age and life expectancy increases.
This study was supported by the Sagol Institute for Longevity Research, the Thompson Family Foundation Alzheimer’s Disease Research Fund, and the Estate of Daisy Pinchas.
The successful completion of this Phase 1b trial for IBC-Ab002 offers a beacon of hope for individuals affected by Alzheimer's disease. By shifting the focus from solely targeting amyloid plaques to rejuvenating the body's immune system, this research opens up a promising new avenue for therapeutic intervention. The potential to restore the immune system's protective functions and mitigate age-related neuroinflammation could fundamentally change how we approach Alzheimer's and other neurodegenerative disorders. This innovative strategy underscores the importance of a holistic understanding of disease mechanisms and the power of interdisciplinary scientific collaboration.